Startseite
Diese Website ist für medizinisches Fachpersonal bestimmt.

Navigator zur Lungenfibrose – Modul 4: Das schwierige Gespräch

Teilen

Beschreibung

Diese Veranstaltung wird durch einen unabhängigen Fortbildungszuschuss von BMS unterstützt. Dieses Online-Fortbildungsprogramm richtet sich an medizinisches Fachpersonal weltweit, mit Ausnahme des Vereinigten Königreichs.

Erhalten Sie von dem Experten Dr. med. Fernando Martinez einen praktischen Leitfaden zur Integration einer proaktiven Vorsorgeplanung (Advance Care Planning, ACP) in das langfristige ILD-Management. In dieser Sitzung wird untersucht, wie objektive klinische Auslöser, wie z. B. Funktionsverlust und das ILD-GAP-Stadium, darauf hinweisen, dass parallel zur krankheitsmodifizierenden Behandlung Gespräche über unterstützende Maßnahmen eingeleitet werden müssen.

Dies ist Modul vier von vier. Die Module eins, zwei und drei finden Sie hier.

Highlights der Sitzung

  • Leiten Sie Gespräche zur Vorsorgeplanung frühzeitig ein und nutzen Sie dabei objektive klinische Parameter wie das ILD-GAP-Stadium und den Funktionsverlust, anstatt auf akute Krisenereignisse zu warten.
  • Wenden Sie einfühlsame, patientenzentrierte Kommunikationsstrategien an, die Pflegepräferenzen, Behandlungsziele und Eskalationsgrenzen ohne Fachjargon verdeutlichen.
  • Integrieren Sie unterstützende und palliative Versorgungswege parallel zu laufenden antifibrotischen Therapien, um die Lebensqualität der Patienten zu erhalten.
  • Dokumentieren Sie Entscheidungen zur Vorausplanung der Versorgung direkt in gemeinsamen Dashboards, um eine klare multidisziplinäre Transparenz und Kontinuität der Versorgung zu gewährleisten.

Zielgruppe

Diese Fortbildung richtet sich an Pneumologen, Rheumatologen, Thoraxradiologen, Pathologen, Fachkrankenschwestern und -pfleger in der Pneumologie sowie Arzthelfer und -assistenten, die eine zentrale Rolle bei der Diagnose und Behandlung von IPF und PPF spielen. Sie richtet sich außerdem an Allgemeinmediziner, Atemtherapeuten, Apotheker und andere multidisziplinäre medizinische Fachkräfte, die an der Versorgung von Patienten mit Lungenfibrose beteiligt sind.

Referenten

Dr. Fernando Martinez ist Professor in der Abteilung für Lungenheilkunde und kommissarischer Vorsitzender der Abteilung für Medizin an der University of Massachusetts Chan Medical School in Worcester, Massachusetts. Er verfügt über einen MD- und einen MS-Abschluss und ist ein führender Kliniker und Forscher, der sich seit langem für die akademische Medizin, die Patientenversorgung und interdisziplinäre Strategien in der Lungenheilkunde engagiert.

Offenlegungen

Gemäß den EBAC®-Richtlinien haben alle an diesem Programm teilnehmenden Referenten und Moderatoren potenzielle Interessenkonflikte offengelegt oder angegeben, die ihre Vorträge beeinflussen könnten. Das Organisationskomitee bzw. der Kursleiter ist dafür verantwortlich, sicherzustellen, dass alle potenziellen Interessenkonflikte, die für die Veranstaltung relevant sind, den Teilnehmern vor Beginn der Fortbildungsmaßnahmen offengelegt werden.

Dr. Fernando Martinez, Dozent dieser Veranstaltung, hat finanzielle Beziehungen innerhalb der letzten 36 Monate zu den folgenden nicht teilnahmeberechtigten Unternehmen offengelegt:​​Berater für Lung Therapeutics; Berater, Gutachter und Referent für Boehringer Ingelheim und Chiesi; Mitglied des DSMB für Pliant; Forscher für AstraZeneca, Bristol Myers Squibb, Chiesi, DevPro und Vicore.

Die Mitarbeiter von MedAll sowie die Planer und Gutachter haben keine relevanten finanziellen Beziehungen zu nicht teilnahmeberechtigten Unternehmen offenzulegen.

EBAC®-CME-Informationen:

Diese Veranstaltung wurde gemäß den Akkreditierungsanforderungen und -richtlinien des European Board for Accreditation of Continuing Education for Health Professionals (EBAC) geplant und durchgeführt.

MedAll ist seit 2025 ein von der EBAC akkreditierter Anbieter. Das European Board for Accreditation of Continuing Education for Health Professionals (EBAC) akkreditiert Fortbildungsprogramme (CE) für die internationale medizinische Fachwelt.

Dieses Programm ist vom European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) für 15 Minuten effektive Fortbildungszeit akkreditiert.

In Übereinstimmung mit den EBAC-Richtlinien haben alle an diesem Programm teilnehmenden Referenten/Vorsitzenden potenzielle Interessenkonflikte offengelegt oder angegeben, die zu einer Voreingenommenheit in den Vorträgen führen könnten. Das Organisationskomitee/der Kursleiter ist dafür verantwortlich, sicherzustellen, dass alle potenziellen Interessenkonflikte, die für die Veranstaltung relevant sind, dem Publikum vor Beginn der Fortbildungsaktivitäten offengelegt werden.

EBAC® unterhält jeweils eine Vereinbarung über die gegenseitige Anerkennung der inhaltlichen Gleichwertigkeit mit dem US Accreditation Council for CME (ACCME) und dem Royal College of Physicians and Surgeons of Canada.

Durch eine Vereinbarung zwischen dem European Board for Accreditation of Continuing Education for Health Professionals (EBAC®) und der American Medical Association können Ärzte externe EBAC®-CME-Punkte in AMA PRA Category 1 Credits umwandeln. Informationen zum Verfahren zur Umwandlung von EBAC®-Punkten in AMA-Punkte finden Sie auf der AMA-Website. Andere Angehörige der Gesundheitsberufe können von der AMA eine Teilnahmebescheinigung für eine Veranstaltung erhalten, die zur Umwandlung in AMA PRA Kategorie-1-Punkte berechtigt.

Der Accreditation Council for Continuing Medical Education (ACCME) und das Royal College of Physicians and Surgeons of Canada haben mit EBAC eine Vereinbarung über die wesentliche Gleichwertigkeit der Akkreditierungssysteme geschlossen.

EBAC® ist Mitglied der International Academy for CPD Accreditation (IACPDA) und Partnermitglied der International Association of Medical Regulatory Authorities (IAMRA).

So erhalten Sie Ihre EBAC®-CME-Fortbildungspunkte:

Um Ihre CME-Fortbildungspunkte zu erhalten und Ihr Zertifikat zu erwerben, nehmen Sie bitte an der Veranstaltung teil und füllen Sie am Ende die Bewertung aus. Nach Abschluss der Bewertung erhalten Sie einen Link zu Ihrem Zertifikat.

Teilnahmekosten

Die Teilnahme an diesem Programm ist kostenlos.

Diese Fortbildungsmaßnahme ist ab dem 1. November 2026 aktiv und läuft am 30. September 2027 aus.

Geschätzte Dauer für die Absolvierung dieser Maßnahme: 15 Minuten

Lernziele

Am Ende dieser Aktivität werden die Teilnehmer in der Lage sein:

  • Risikostratifizierung, hochauflösende Bildgebung und multidisziplinäre Beurteilung einzubeziehen, um IPF und PPF frühzeitig und genau von anderen ILDs zu unterscheiden und zu diagnostizieren.
  • Multidisziplinäre Diagnose- und Behandlungsstrategien umzusetzen, um die rechtzeitige Erkennung, Überweisung und koordinierte Versorgung von Patienten mit PF zu verbessern.
  • Kenntnisse über Wirkmechanismen und klinische Evidenz bei Behandlungsentscheidungen anzuwenden, einschließlich der Patientenauswahl und des Zeitpunkts der Therapie.

Ähnliche Communities

Alle anzeigen

Ähnliche Veranstaltungen und On-Demand-Videos

Computer generated transcript

Warning!
The following transcript was generated automatically from the content and has not been checked or corrected manually.

So here we are 18 months later, um, we're trying to impress upon you the value of having some type of a dashboard that would give you sort of hints during the management of the patient. This is now a new kind of flag, and it wasn't that one that's not necessarily related to any specific medication, because here you are sitting with Margaret, you've heard her little uh components there. Uh, and over the last 18 months, you know that she's had an elevated gap score, so she's at advanced risk for progression. And sure enough, the lung function parameters demonstrate that her forced vital capacity has been steadily going downhill. Her DLCO is pretty poopy, and most of Importantly, she's noticing it. She is now not able to do the same as she was doing before. She's can't go up a flight of stairs, uh, she can't go up a hill, uh, and so part of what we want you to understand within the concept of this sort of holistic multidisciplinary approach is to have a sense that this person is at risk and has had functional decline, but there's been no documentation of uh advanced care approaches. And so here we are, 18 months of monitoring her going downhill, and no one's addressed this conversation. So, the question here is the gap, and by this, I don't mean ILD gap, but I mean the gap in her care, isn't really her numbers, it's that we haven't done a good job in providing this care. And so this is part of what we want to try to impress upon you the importance of looking at something like, so this is your hypothetical, uh, dashboard, and what you're looking at is, OK, there's a little Warning on Margaret, uh, who's got, uh, rheumatoid arthritis and associated ILD. She's had an elevated gap stage, so sort of physiologically and clinically, we know she's at risk. In fact, we've documented that there's progression in her pulmonary functions, and she's symptomatically noticing it. And when we look at our, our concepts of advanced uh care planning, That there's just no clear documentation that we've addressed, uh, what she wants, uh, how she wants to be managed, goals of care, place of care, what she wants to do therapeutically and non-ph pharmaco therapeutically for sort of escalation preferences, and there's no evidence that there's been any advanced care planning in her record. Uh, and I think that, that's where we want. To adjust ourselves, our practice pattern, to avoid this gap in care, which is to address the progressive nature of this disorder. So here we come back to, um, to Margaret. Uh, we, we've got a clinician who's talking with her, uh, and, and I want you to sort of to, to look at the way this interaction takes place, uh, and think about it if this were you, uh, what was good. What was that good? What could have been done better? What tools could I have used to better support this, uh, discussion and, and see what, how you guys would, would, would manage this, uh, in, uh, in Margaret's case. Margaret, good to see you. So your numbers, the breathing test has dropped again, and your gap stage is now a 2, which does change the trajectory conversation. I noticed there's no advanced care planning documentation on file, so we should really get that sorted today. It's just a form, nothing to worry about. A form. Is this because it's getting worse? Well, the decline does meet, um, progression thresholds, but let's not get ahead of ourselves. Basically, we document your preferences, resuscitation, escalation, that kind of thing. So it's all on file. Some people involve family, that's an option. Does that sound OK? I suppose. I'd have to think. Great. Reception can print the paperwork and we'll pick it up at your next visit. You're doing really well, all things considered. Right Thank you, doctor. I'll tell you my impression was that this was, you know, it was a well meant discussion, but it was kind of a little bit rushed and a lot of jargon that was being used, um, and as we come back to trying to get a sense of proactive care, using a dashboard like we've sort of presented for you to, to highlight for us, understand we've got an at-risk person, because, you know, there, there's already a, a methodology that's been introduced to identify high-risk individuals. In this case, you, you know that she's at risk. Uh, as you progress in parallel, you're treating, you're monitoring, in her case, you saw her lung function going in that direction, and, and so you're supporting her with management of whatever therapeutic approach you've taken. At the same time, we wanna have you be able to understand in a person like Margaret. It's important to be able to be proactive in asking, what do you wanna do? What matters to you? What, what are your goals, uh, Margaret? Um, how do you wanna achieve those? Do you wanna do it pharmacologically, non-pharmacologically? Uh, do you wanna do it here or you wanna do it in a different location? And all of that has to be documented so that all of your colleagues that are involved in her care get a good sense of, of this approach to proactive management from the earliest stage of disease. To what we do as the stage progresses in appropriately establishing goals, plans, and maximizing satisfaction for all involved, particularly Margaret. Uh, and so this advanced care planning is not really the end of treatment. It's sort of like a safety rail that runs in parallel to, to maximize the outcomes that occur. So if, if I were gonna take away my impressions from, from this, uh, this presentation, the goal of what we're trying to achieve is that advanced care planning is. Longitudinal. It is, it's not dealing with whenever there's a crisis, uh, it is something that's based on the, the baseline assessment and then a very careful discussion with the patient of what the patient wants. Where she wants to do the care and, and what she wants as her ultimate goals, that, that same dashboard that guards adherence should aid you in management the conversation. This documentation of those discussions in your advanced care plan is gonna be useful for you, for Margaret, and for any other clinician that's involved in her care. And, and the idea of being supportive and being able to provide disease modifying therapy which we now have sort of runs in parallel. That, that's an, an advantage for you. It's an advantage most importantly for the patient. And so neither of those cancels the other. They're this joint uh care. I warned you this was coming again. So here's your poll. Again, the same question we asked earlier, how confident are you that you would recognize and act on early ILD management in a patient like Margaret? Same options from not at all confident all the way to completely confident. Uh, and so let's see how that's changed over the course of the last hour. All right. Here we come back to Margaret. Uh, so you, you know, gone through the diagnosis. Um, we, we've sort of asked Margaret, OK, listen, what do you think, uh, you would have wanted, uh, to have happened earlier? You, from the patient's point of view, it was important insight. What's your stance, Margaret? Let's see what she says. I don't think anyone did anything wrong, exactly, but my care team knew my lungs could be affected. I didn't. I wish that had been checked before I could feel anything, and I wish someone had clearly overseen the results and the conversation about what matters to me. I'd have been ready for that much earlier than anyone asked. All right. So, most importantly, when you participate in a program like this, to try to remember at least one thing that, that you're going to do differently. Uh, and so these are, these are potentially options, uh, for you to consider. It's most importantly for you and your practice setting. Uh, know what a risk profile looks like, um, so that you, you're establishing some thoughts regarding how you want to interact with Margaret before any symptoms occur, certainly before there's any crisis that's occurred. Uh, put that as a flag to yourself and act on that, uh, when you have an opportunity, um, give every flag an owner, so whenever you're documenting these components, in particularly if you have structured reports, which always simplify things, make sure that there's good documentation that you address these components of the advanced care planning. So that the multidisciplinary discussion, which is the gold standard for all of us in diagnosis and management, becomes part of the routine for all clinicians that are involved with managing Margaret during the course of her, of her journey, uh, and then, you know, treat tolerability as a treatment. You know, all of these drugs have challenging components, some less, some more. Be proactive in managing some of the particularly GI side effects with the patient. There is a, a, a broad, it's amazing the, the level of advance we've made in therapy and it's continuing to proceed. So, so Margaret's gonna have a lot of options, and so you're gonna have to really be able to document all of that, make sure that you've had those discussions with Margaret. They're recorded in your, in your action plan, and you close the loop with the patient. Because what, what's most important is what matters to her during the course of this longitudinal journey with you and aiding her with her care.